New hope for rare skin cancer: Post-Transplant drug aims to stop relapse

NCT ID NCT07178457

Not yet recruiting Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 41 times

Summary

This study tests whether giving the drug brentuximab vedotin after a stem cell transplant can prevent early relapse in people with advanced cutaneous T-cell lymphoma (CTCL). About 84 adults aged 18-70 with CD30-positive mycosis fungoides who have had at least one prior treatment and are in remission after transplant will be randomly assigned to receive the drug or a placebo. The goal is to see if this approach improves how long patients live without their cancer returning.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA (CTCL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRENTUXIMAB VEDOTIN CUTANEOUS T CELL LYMPHOMA (CTCL)